PMID- 29112900
OWN - NLM
STAT- MEDLINE
DCOM- 20180727
LR  - 20220410
IS  - 1873-264X (Electronic)
IS  - 0731-7085 (Linking)
VI  - 149
DP  - 2018 Feb 5
TI  - Serum metabonomics study of the hepatoprotective effect of amarogentin on 
      CCl(4)-induced liver fibrosis in mice by GC-TOF-MS analysis.
PG  - 120-127
LID - S0731-7085(17)31694-1 [pii]
LID - 10.1016/j.jpba.2017.10.029 [doi]
AB  - Amarogentin (AG) is a secoiridoid glycoside that is mainly extracted from the 
      traditional Chinese medicine Swertia and Gentiana, which have been widely used in 
      clinical practice to treat liver disease. However, the exact hepatoprotective 
      mechanism of AG was still looking forward to further elucidation by far. In this 
      study, C57BL/6 mice were divided into the following three groups: control, model 
      and AG. Fibrosis was induced by CCl(4). Mice were orally treated with 100mg/kg AG 
      or with normal saline as a control. At the end of the experiment, the validity of 
      the model and the hepatoprotective effects of AG were examined by histopathology 
      and biochemical indicators. Metabonomics technology was further performed to 
      systematically evaluate the endogenous metabolite profiles. Gas chromatography 
      time-of-flight mass spectrometry (GC-TOF-MS) technology with pattern recognition 
      analysis, including principal component analysis (PCA) and orthogonal partial 
      least square discriminant analysis (OPLS-DA), showed a clear separation of the 
      model group and the control group, with the AG treatment group located much 
      closer to the control group than the model group, which was consistent with the 
      results of biochemical and histopathological assays. Moreover, nine potential 
      biomarkers were identified to elucidate the drug mechanism of AG, which may be 
      related to pathways of amino acid and fatty acid metabolism.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Zhang, Ya
AU  - Zhang Y
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China.
FAU - Zhang, Meng
AU  - Zhang M
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China.
FAU - Li, Hua
AU  - Li H
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China.
FAU - Zhao, Hang
AU  - Zhao H
AD  - Department of Pharmacy, the 456th Hospital of the People's Liberation Army, Jinan 
      250031,China.
FAU - Wang, Fang
AU  - Wang F
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China.
FAU - He, Qiaoyan
AU  - He Q
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China.
FAU - Zhang, Tian
AU  - Zhang T
AD  - Xi'an Day Natural Inc., F501 Gazelle Valley, Pioneering R&D Park, 69 Jinye Road, 
      Xi'an 710077, China.
FAU - Wang, Siwang
AU  - Wang S
AD  - Department of Natural Medicine, School of Pharmacy, Fourth Military Medical 
      University, 169 West Changle Road, Xi'an 710032, China. Electronic address: 
      wangsiw@fmmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20171031
PL  - England
TA  - J Pharm Biomed Anal
JT  - Journal of pharmaceutical and biomedical analysis
JID - 8309336
RN  - 0 (Biomarkers)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Iridoids)
RN  - 0 (Protective Agents)
RN  - 5L82GT5I0W (amarogentin)
RN  - CL2T97X0V0 (Carbon Tetrachloride)
SB  - IM
MH  - Animals
MH  - Biomarkers/blood
MH  - Carbon Tetrachloride/toxicity
MH  - Discriminant Analysis
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/chemistry/*pharmacology/therapeutic use
MH  - Gas Chromatography-Mass Spectrometry/instrumentation/methods
MH  - Humans
MH  - Iridoids/chemistry/*pharmacology/therapeutic use
MH  - Liver/*drug effects/pathology
MH  - Liver Cirrhosis/blood/chemically induced/*drug therapy/pathology
MH  - Male
MH  - Medicine, Chinese Traditional/methods
MH  - Metabolic Networks and Pathways/drug effects
MH  - Metabolome/drug effects
MH  - Metabolomics/instrumentation/*methods
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Principal Component Analysis
MH  - Protective Agents/chemistry/*pharmacology/therapeutic use
MH  - Tandem Mass Spectrometry/instrumentation/methods
OTO - NOTNLM
OT  - Amarogentin
OT  - GC-TOF-MS
OT  - Liver fibrosis
OT  - Metabonomics
EDAT- 2017/11/08 06:00
MHDA- 2018/07/28 06:00
CRDT- 2017/11/08 06:00
PHST- 2017/06/30 00:00 [received]
PHST- 2017/10/25 00:00 [revised]
PHST- 2017/10/26 00:00 [accepted]
PHST- 2017/11/08 06:00 [pubmed]
PHST- 2018/07/28 06:00 [medline]
PHST- 2017/11/08 06:00 [entrez]
AID - S0731-7085(17)31694-1 [pii]
AID - 10.1016/j.jpba.2017.10.029 [doi]
PST - ppublish
SO  - J Pharm Biomed Anal. 2018 Feb 5;149:120-127. doi: 10.1016/j.jpba.2017.10.029. 
      Epub 2017 Oct 31.